Amarin (AMRN) Stock: This Bull Isn’t Bullish Enough
Amarin (AMRN) has been Wall Street’s biggest standout of 2018, with shares skyrocketing nearly 240%. The biggest question for investors, then, is whether …
Why Does This Top Analyst Make Amazon (AMZN) One of His Best Picks for 2019?
Amazon (AMZN) is clearly the most ubiquitous name in the world of e-commerce, and it has edged its way into physical stores as …
Top Analyst Sets Expectations on Netflix (NFLX) Ahead of 4Q:18 Results
It’s been a tough few months for Netflix (NFLX) investors. After it reached all-time highs last June, a rare subscriber miss and a late-year stock …
Roku (ROKU) Stock: Next Stop, $59?
Roku (ROKU) stock jumped 25% yesterday on the back of the news that the streaming service increased active accounts by 40% to over …
Canaccord Continues to Hold Bullish View on Qualcomm (QCOM) Stock; Here’s Why
The US Federal Trade Commission (FTC) versus Qualcomm (QCOM) case started Friday, January 4, 2019, with a 10-day non-jury trial. The FTC’s complaint …
3 Reasons Why Advanced Micro Devices (AMD) Stock Is an Attractive Pick
The past month has been a weird time for stocks. Though the US and China agreed to a temporary trade war truce, the …
Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks
Hedge fund manager Mitchell J. Blutt of the $1.
A Glimpse Into Alibaba’s (BABA) Earnings Call with Analysts
To get a full understanding of just how well Alibaba (NYSE:BABA) is doing, it’s worth checking on the e-commerce giant’s fiscal first-quarter earnings …
Trevena (TRVN) Set for Multiple Catalysts in 2018
Trevena’s (NASDAQ:TRVN) pain drug oliceridine is expecting an FDA decision coming November 2. Furthermore, the FDA has informed the company that it intends to …